BioLineRx Ltd. (BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, announced Monday that the U.S. Food and Drug Administration or FDA has approved APHEXDA (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood. This is for collection and subsequent autologous transplantation in patients with multiple myeloma.
from RTT - Before the Bell https://ift.tt/FqW8g6Z
via IFTTT
No comments:
Post a Comment